Amneal Pharmaceuticals, Inc. AMRX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $181.32M+459% | $127.93M+273% | $57.62M+139% | $51.24M+138% | $32.42M+127% | ||
| $33.51M+18.4% | $31.95M+15.1% | $30.96M+16.7% | $29.85M+14.3% | $28.3M+9.1% | ||
| $19.51M-33.0% | $22.43M-22.9% | $25.53M-5.2% | $28.53M+34.1% | $29.11M+78.6% | ||
| $97.7M— | $120.57M— | $138.83M— | —— | —— | ||
| $128.72M-2.2% | $87.03M-33.3% | $118.83M+16.9% | $131.12M+29.7% | $131.59M+13.6% | ||
| $9.37M-84.5% | $21.32M-90.9% | $69M-53.7% | $46.11M— | $60.34M— | ||
| $33.06M— | $20.17M— | —— | —— | —— | ||
| -$4.91M-230% | -$4.73M-211% | -$6.08M-136% | -$5.21M-1.6% | -$1.49M+83.9% | ||
| —— | —— | —— | —— | —— | ||
| $305.84M-0.4% | $339.99M+15.2% | $327.76M+4.8% | $351.08M+39.1% | $306.92M+44.2% | ||
| $65.08M+16.4% | $70.06M+34.9% | $63.45M+36.0% | $68.09M+64.7% | $55.89M+30.8% | ||
| $19.16M+109% | $15.51M+5.9% | $13.11M-61.4% | $9.3M-70.3% | $9.15M-71.2% | ||
| —— | —— | —— | —— | —— | ||
| -$116.18M-90.3% | -$112.26M-78.2% | -$82.87M-5.4% | -$81.12M-13.6% | -$61.03M+21.0% | ||
| $2.83B— | $2.69B— | $170M— | —— | —— | ||
| $1.93M+61.4% | $1.96M+69.8% | $1.56M+48.9% | $1.52M+81.8% | $1.2M+149% | ||
| $44.94M+101% | $22.28M+180% | $22.34M+189% | $22.41M+190% | $22.38M+196% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | -$234.4M+4.6% | -$227.8M-2.2% | ||
| -$2.23M-70.3% | -$1.68M-67.0% | -$2.21M-3,302% | -$1.52M-314% | -$1.31M— | ||
| $136.01M+711% | $194.52M+907% | $160.06M+1,027% | $34.05M— | $16.78M— | ||
| $197.98M-22.5% | $197.85M-24.9% | $217.05M-16.2% | $239.62M-0.4% | $255.33M+18.1% | ||
| $27.39M+234% | $21.33M+30.3% | $23.74M+93.3% | $18.73M— | $8.19M— | ||
| $19.51M-33.0% | $22.43M-22.9% | $25.53M-5.2% | $28.53M+34.1% | $29.11M+78.6% | ||
| $206.6M-14.2% | $223.57M-5.3% | $240.48M+5.9% | $245.36M+8.9% | $240.82M+6.2% | ||
| —— | —— | —— | $6.7M+333% | -$2.08M— | ||
| —— | —— | —— | -$2K— | -$1.04M— | ||
| —— | —— | —— | $50.12M+203% | $47.82M+250% | ||
| $33.06M— | $20.17M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $75.65M-22.3% | $85.96M-11.0% | $92.27M+13.0% | $93.5M+25.7% | $97.3M+34.4% | ||
| -$4.91M-230% | -$4.73M-211% | -$6.08M-136% | -$5.21M-1.6% | -$1.49M+83.9% | ||
| $19.16M+109% | $15.51M+5.9% | $13.11M-61.4% | $9.3M-70.3% | $9.15M-71.2% | ||
| $33.51M+294% | $28.78M+242% | $14.69M+384% | $12.11M+229% | $8.51M— | ||
| —— | —— | —— | —— | —— | ||
| —— | $2.09M— | $1.57M— | $1.05M— | $523.5K— | ||
| —— | $74.97M+105,496% | $56.25M+38.3% | $37.52M-53.8% | $18.8M-84.6% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $0-100% | ||
| -$2.91B-17,233% | -$2.81B-1,388% | $2.48B+675% | -$16.72M+96.0% | -$16.77M+96.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $27.39M+234% | $21.33M+30.3% | $23.74M+93.3% | $18.73M— | $8.19M— | ||
| —— | —— | —— | —— | —— | ||
| $240.77M-4.1% | $269.93M+11.0% | $264.31M-0.7% | $282.99M+34.0% | $251.03M+37.9% | ||
| $240.77M-4.1% | $269.93M+11.0% | $264.31M-0.7% | $282.99M+34.0% | $251.03M+37.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Amneal Pharmaceuticals, Inc. generate?
- Amneal Pharmaceuticals, Inc. (AMRX) generated $305.8M in operating cash flow over the trailing twelve months.
- What is Amneal Pharmaceuticals, Inc.'s free cash flow?
- After $65.1M of capital expenditures, Amneal Pharmaceuticals, Inc.'s free cash flow was $240.8M over the trailing twelve months, down 4.1% year over year.
- Where does Amneal Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Amneal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
